Effects of exogenous porcine growth hormone administration between 30 and 60 kilograms on the subsequent and overall performance of pigs grown to 90 kilograms

Twenty-eight barrows were used to investigate the effects of exogenous porcine growth hormone (pGH) administration (0 and 100 micrograms.kg-1.d-1) between 30 and 60 kg on the subsequent and overall performance and carcass composition of pigs grown to 90 kg. The pGH was administered by daily i.m. injection and all pigs were fed one diet. Control animals were pair-fed to the intake noted for pGH-treated pigs between 30 and 60 kg and all pigs were fed ad libitum from 60 to 90 kg. Pigs administered pGH had an improved rate (36%) and efficiency (28%) of gain and an improved protein accretion rate (46%) compared to excipient-treated pigs. Pigs previously treated with pGH continued to exhibit superior (P less than .01) rate and efficiency of gain, and the gain was associated with enhanced protein accretion during the quiescent (postinjection) period compared with excipient counterparts. Administration of pGH between 30 and 60 kg reduced carcass fat and increased carcass protein and water at 90 kg, although fat accretion rate was comparable to that of control pigs. Results indicate that, to varying degrees, the stimulatory effects of pGH on growth performance are sustained following cessation of hormone treatment.     

Determination of the temporal relationship between porcine growth hormone, serum IGF-1 and cortisol concentrations in pigs

We found previously that porcine growth hormone (pGH) causes an increase in growth rate with a concurrent improvement in carcass composition in pigs. The somatomedin, insulin-like growth factor 1 (IGF-1), is though to play a major role in mediating some of the anabolic actions of GH, while the glucocorticoid hormones are potential counter-regulators of these effects. The present study was conducted to determine the temporal and dose-response relationship between GH administration and serum IGF-1 and cortisol concentrations in pigs. Twelve Yorkshire barrows, fitted with femoral artery catheters, were injected (im) with either 0, 10, 100 or 1,000 micrograms/kg pGH. Blood sampling began 40 min prior to pGH injection and was continued for 37 h. Serum GH, IGF-1 and cortisol concentrations were determined by radioimmunoassay. In control animals, serum GH concentrations ranged from 1.6 to 5.7 ng/ml over 37 h. In the animals treated with increasing doses of pGH, peak serum GH concentrations reached 28, 112 and 286 ng/ml and levels remained elevated for 4, 12 and 24 h, respectively. Serum IGF-1 concentrations were elevated by pGH after a lag time of 4 to 6 h. When the IGF-1 concentrations were integrated over time, the response appeared to be dose-dependent, with an ED50 of 710 micrograms/kg body weight (BW). Data for serum cortisol concentrations showed a great deal of individual variation. A transient increase in cortisol was observed, but only in the group treated with 1,000 micrograms pGH/kg BW. Cortisol levels returned to baseline 2 h after pGH injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of porcine growth hormone on glucose metabolism of pigs: I. Acute and chronic effects on plasma glucose and insulin status

The acute and chronic effects of porcine growth hormone (pGH) administration on glucose homeostasis of pigs were investigated in the present study. Twelve Yorkshire barrows (average BW = 65 kg) fitted with femoral artery catheters were allotted to three groups. Pigs received acute, intra-arterial injections of either pituitary pGH, a recombinantly derived pGH analog (ppGH or rpGH, 100 micrograms/kg BW) or saline. Acute injection of pGH did not affect fasting plasma glucose or insulin status. Pigs then were treated daily by i.m. injection for 24 d with 70 micrograms ppGH/kg BW. Serum glucose and insulin concentrations during the fed and fasted states were higher in pGH-treated than in control pigs. On d 25, an acute intra-arterial injection of ppGH (100 micrograms/kg BW) elicited increases in plasma glucose and insulin in pigs chronically treated with pGH. The area circumscribed by the glucose and insulin response curves 5 min to 7 h postinjection was 40% (P less than .005) and 177% (P less than .001), respectively, higher in ppGH-treated than in control pigs. These data indicate that pGH does increase plasma glucose and insulin in the fed and fasted states; however, this response is only observed after chronic pGH administration. In addition, pGH is capable of increasing plasma glucose and insulin acutely in the pig. This effect, however, only is observed in pigs treated chronically with pGH. The mechanisms by which pGH elicit these effects on glucose homeostasis are not known.     

Interaction of dietary protein content and exogenous porcine growth hormone administration on protein and lipid accretion rates in growing pigs

Sixty-six intact male pigs were used to investigate the relationships between exogenous porcine growth (pGH) administration (0, excipient-treated, and .09 mg recombinant pGH.kg-1.d-1) and dietary protein content (8.3, 11.4, 14.5, 17.6, 20.7 and 23.8%) on protein and lipid accretion rates over the live weight range of 30 to 60 kg. Feed intakes were restricted (1.84 kg.pig-1.d-1) and pGH was administered daily by i.m. injection. Rate of protein deposition increased with increasing dietary protein up to 17.6 and 20.7%, respectively, for control and pGH-treated pigs; both growth and protein deposition were enhanced by pGH on the four higher protein diets but remained unaffected by pGH administration to pigs given the two lowest protein diets. Plasma IGF-I concentration was elevated by pGH administration in pigs given the four higher protein diets but unaffected by pGH with the two lowest protein diets. Rate of fat deposition was depressed on all dietary protein treatments by pGH administration; carcass fat content of control and pGH-treated pigs declined with each increase in dietary protein up to 17.6 and 23.8%, respectively. The results demonstrate that pGH acts independently on protein and lipid metabolism.     

Stimulation of swine growth by porcine growth hormone

Highly purified porcine growth hormone (pGH; USDA-B1) was administered by im injection (22 micrograms X kg body weight-1 X d-1) to rapidly growing Yorkshire barrows for 30 d. Growth hormone significantly increased growth rate (10%), feed efficiency (4%), cartilage growth and muscle mass. However, pGH did not affect carcass adipose tissue mass. Intramuscular lipid content of the longissimus was increased 50% by pGH administration. Plasma pGH concentration was elevated (7- to 11-fold) for 3 to 5 h post-injection. Chronic administration of pGH depressed pituitary GH content and concentration approximately 45%. No GH antibodies were detected in the plasma of GH-treated swine. Plasma somatomedin-C concentration was increased 55% by GH treatment 3 h post-injection. Plasma glucose and insulin concentrations were both significantly increased in GH-treated swine, suggesting that the animals had developed a state of insulin resistance. Plasma-free fatty acid concentration tended to be higher in GH-treated animals. Treatment of swine with pGH significantly decreased plasma blood urea nitrogen. Assessment of animal health during the trial and postmortem indicated that pGH administration did not have any adverse effects. In summary, treatment of young, rapidly growing swine with pGH stimulated growth performance without affecting animal health or inducing the production of GH antibodies.     

Stimulation of pig growth performance by porcine growth hormone: determination of the dose-response relationship

The present study was undertaken to determine the relationship between dose of porcine growth hormone (pGH) and growth performance of pigs. Porcine GH was administered daily for 35 d [buffer-injected control = (C); 10 micrograms/kg body weight (BW) = (L); 30 micrograms/kg BW = (M); 70 micrograms/kg BW = (H)] to barrows (initial wt = 50 kg). Growth rate was significantly increased by pGH (14% for H dose vs C). Feed efficiency was increased in a dose-related manner (L = 7%, M = 10%, H = 17%) by pGH. There was a concurrent change in carcass composition of pGH-treated pigs. The H dose of pGH decreased the percentage of carcass lipid by 25% (P less than .05). Muscle mass was significantly increased in H vs C pigs (31 vs 26 kg). Serum insulin-like growth factor 1 (IGF-1) concentration increased in a manner that was linearly related to the pGH dose (r = .87). No antibodies to pGH were detected in any of the pigs. In summary, these results extend our earlier findings that pGH increases growth performance markedly. Based on the present findings it appears that the maximally effective dose of pGH is greater than 70 micrograms.kg BW-1.d-1 since several indices of the growth-promoting and metabolic effects of pGH (% carcass protein, % carcass lipid and feed efficiency) had not plateaued.     

Interrelationships between sex and exogenous growth hormone administration on performance, body composition and protein and fat accretion of growing pigs

Forty-five pigs with an average initial live weight of 60 kg were used to investigate the effects of daily exogenous porcine pituitary growth hormone administration at two dose levels (pGH; 0, excipient buffer injected, and 100 micrograms.kg-1.d-1) for a 31-d period on the performance and body composition of boars, gilts and barrows allowed to consume feed ad libitum. Excipient boars consumed less feed, exhibited faster and more efficient growth (P less than .01) and produced less fat and more protein and water (P less than .01) in the empty body compared with excipient barrows, which in turn contained more fat and less water (P less than .05) in the empty body than did excipient gilts. These differences were largely eliminated by pGH administration, which induced differential effects in growth performance and body composition in boars, gilts and barrows. Growth hormone administration improved growth rate by 13, 22 and 16% and feed conversion efficiency by 19, 34 and 32% in boars, gilts and barrows, respectively. The reduction of body fat content (g/kg) elicited by pGH was 22, 36 and 33% for boars, gilts and barrows, respectively, with a corresponding increase (P less than .01) of body protein and water content. The magnitude of the pGH responses was greatest for gilts and barrows compared with boars, negating intrinsic sex-effect differences in growth performance and body composition of pigs. Pigs used in this study and treated with pGH exhibited a rate of protein deposition (approximately 225 g/d) far greater than previously reported, and as such redefine the genetic capacity for lean tissue growth by the pig.     

Growth hormone increases whole-body protein turnover in growing pigs.

Ten pigs with an average initial live weight of 65 kg were used to investigate the effects of daily exogenous porcine pituitary growth hormone (pGH; .1 mg.kg-1.d-1) for a 13-d period on N retention and whole-body protein turnover. Feed intake was restricted to both the control (treated with excipient) and pGH-treated groups to ensure that animals in each group consumed equal amounts. Whole-body protein turnover was estimated from the excretion of 15N in urinary urea and ammonia after a single oral dose of [15N]glycine. Nitrogen balance and whole-body N flux were increased by 35 to 40% with pGH treatment (P less than .001). Protein synthesis and breakdown were increased by 56 and 59% (P less than .001), respectively, in pGH-treated pigs relative to controls. These higher rates of protein turnover seemed to lower slightly the efficiency of the metabolic process for protein deposition. However, the absolute increment in protein synthesis rate was greater than that for breakdown, leading to the increased net N retention. Thus, pGH treatment improved the utilization of dietary amino acids for protein deposition.     

Chronic effects of recombinant porcine growth hormone on adrenal weight and activity in pigs

This study was conducted to examine serum cortisol concentrations and adrenal cortisol output in pigs treated chronically with recombinant pGH (rpGH) at a maximally effective anabolic dose. Recombinant pGH (140 micrograms/kg body weight) was administered daily to eight barrows for 77 d. At slaughter, adrenal glands were removed, weighed and sliced; slices of fresh adrenal tissue were incubated for 1 h in the presence or absence of ACTH. Recombinant pGH increased adrenal weight by 39%. This change was accompanied by an inversely proportional reduction of in vitro cortisol output per gram of tissue, with the net result that total cortisol output per adrenal per kilogram of BW was unaltered, as was cortisol output in the presence of ACTH. Serum cortisol concentrations were measured in 10 barrows fitted with femoral artery catheters and treated daily with 0 or 140 micrograms rpGH/kg BW for 8 d. Basal and ACTH-stimulated cortisol concentrations were not altered by rpGH treatment. These results do not support our earlier speculation that a pGH-dependent increase in adrenal weight is associated with a chronic increase in adrenal activity, but rather demonstrate that corticosteroid output is tightly regulated and remains constant despite a marked increase in the size of the adrenal glands.     

Interrelationships between energy intake and endogenous porcine growth hormone administration on the performance, body composition and protein and energy metabolism of growing pigs weighing 25 to 55 kilograms live weight

Thirty-six barrows were used in a 2 X 3 factorial experiment to investigate the effects of porcine growth hormone (pGH) administration (USDA-pGH-B1; 0 and 100 micrograms.kg body weight-1.d-1) and three levels of feeding of a single diet (EI; ad libitum, 1.64 and 1.38 kg/d) on the performance, body composition and rates of protein and fat deposition of pigs growing over the live weight phase 25 to 55 kg. Raising EI resulted in linear increases in growth rate and in protein and fat accretion but had no effect on the feed to gain ratio (F/G). Carcass fat content and carcass fat measurements also increased with EI, whereas carcass protein and water decreased (P less than .01). Growth hormone administration resulted in improvements in growth rate (16 to 26%), F/G (23%), protein deposition (34 to 50%) and increases in carcass protein and water at each level of feeding, but reduced ad libitum feed intake (P less than .01), carcass fat content (P less than .01) and carcass fat measurements (P less than .01). Estimated maintenance energy expenditure was increased by pGH administration (2.02 vs 1.72 Mcal digestible energy/d). Results indicate that the effects of pGH on growth performance and energy and protein metabolism were largely independent of, and additive to, the effects of energy intake.     

Pituitary porcine growth hormone (pGH) and a recombinant pGH analog stimulate pig growth performance in a similar manner

This study was conducted to establish the extent to which different doses of pituitary porcine growth hormone (ppGH) increase pig growth performance. Pigs were treated daily for 11 wk with 0, 35 or 70 micrograms ppGH/kg BW. In addition, these effects were compared with those produced by treating pigs with 0, 35, 70 or 140 micrograms.kg BW-1.d-1 of a recombinantly derived analog of porcine growth hormone (rpGH). This analog lacks the first seven amino acids at the NH2 terminus. Growth rate was increased similarly by ppGH and rpGH (the maximal increase was 19%). Feed efficiency was improved by ppGH and rpGH (the maximal response was 25%). This improvement in feed efficiency was associated with a decrease in feed intake (17% with the largest dose of rpGH). Both ppGH and rpGH decreased adipose tissue growth and increased muscle mass. Carcass lipid was decreased by 68% in pigs treated with the largest dose of rpGH. The recombinant pGH analog appeared to be less potent than ppGH in decreasing adipose tissue growth rate. All other parameters measured, however, indicated that rpGH mimicked the biological effects of ppGH (including binding to pig liver membranes and induction of insulin-like growth factor I production). Sensory panel evaluations indicated that neither ppGH nor rpGH affected pork palatability. Larger doses of pGH (greater than 70 micrograms/kg BW) adversely affected pig mobility. This impairment in mobility appears to be due to osteochondrosis. Our findings establish that the rpGH analog is equipotent to ppGH in stimulating growth performance and that pigs can be treated without any significant adverse effects when they are treated with less than 70 micrograms of pGH.kg BW-1.d-1.     

In vitro and in vivo evaluation of effects of a heptanoyl tripeptide, FK-565, on porcine macrophage and lymphocyte function

A series of experiments was performed in vitro and in vivo to determine the influence of FK-565, a heptanoyl tripeptide, on lymphocyte and macrophage function in swine. Compared with values for control cultures, mitogen-stimulated lymphocyte blastogenesis and interleukin-2 production were unaffected in cells preincubated with 0.1, 1.0, and 10.0 micrograms of FK-565/ml. Natural killer cell activity was increased by preincubation with 1.0 microgram of FK-565/ml; however, this increase was not statistically significant. In vitro treatment of porcine alveolar macrophages with FK-565 did not enhance cytolytic activity or bactericidal activity. In in vivo experiments, FK-565 given orally to pigs at concentrations of 6 or 60 micrograms.kg-1.d-1 for 5 days did not affect lymphocyte blastogenesis, interleukin-2 production, or alveolar macrophage bactericidal activity. A trend toward increased natural killer cell activity was evident in pigs treated with FK-565. In contrast, pigs treated with 6 micrograms.kg-1.d-1 had significantly (P less than 0.01) decreased alveolar macrophage cytolytic activity. These data indicate that at the dosages tested, FK-565 is not a suitable immunomodulator for enhancement of nonspecific immunity in swine.     

Stimulation of pig growth performance by porcine growth hormone and growth hormone-releasing factor

The current study was undertaken to determine the effects of human growth hormone-releasing factor [hpGRF-(1-44)-NH2] on growth performance in pigs and whether this response was comparable to exogenous porcine growth hormone (pGH) treatment. Preliminary studies were conducted to determine if GRF increased plasma GH concentration after iv and im injection and the nature of the dose response. Growth hormone-releasing factor stimulated the release of pGH in a dose-dependent fashion, although the individual responses varied widely among pigs. The results from the im study were used to determine the dose of GRF to use for a 30-d growth trial. Thirty-six Yorkshire-Duroc barrows (initial wt 50 kg) were randomly allotted to one of three experimental groups (C = control, GRF and pGH). Pigs were treated daily with 30 micrograms of GRF/kg body weight by im injection in the neck. Pigs treated with pGH were also given 30 micrograms/kg body weight by im injection. Growth rate was increased 10% by pGH vs C pigs (P less than .05). Growth rate was not affected by GRF; however, hot and chilled carcass weights were increased 5% vs C pigs (P less than .05). On an absolute basis, adipose tissue mass was unaffected by pGH or GRF. Carcass lipid (percent of soft-tissue mass) was decreased 13% by GRF (P less than .05) and 18% by pGH (P less than .05). Muscle mass was significantly increased by pGH but not by GRF. There was a trend for feed efficiency to be improved by GRF; however, this was not different from control pigs. In contrast, pGH increased feed efficiency 19% vs control pigs (P less than .05). Chronic administration of GRF increased anterior pituitary weight but did not affect pituitary GH content or concentration. When blood was taken 3 h post-injection, both GRF- and pGH-treated pigs had lower blood-urea nitrogen concentrations. Serum glucose was significantly elevated by both GRF and pGH treatment. This was associated with an elevation in serum insulin. These results indicate that increasing the GH concentration in blood by either exogenous GH or GRF enhances growth performance. The effects of pGH were more marked than for GRF. Further studies are needed to determine the optimal dose of GRF to administer in growth trials and the appropriate pattern of GRF administration in order to determine whether GRF will enhance pig growth performance to the extent that exogenous pGH does.     

Serum cortisol changes in heifers induced by lipid X: A monosaccharide precursor in the biosynthesis of Gram-negative endotoxin

An experiment was conducted to measure the changes in serum cortisol and luteinising hormone (LH) concentrations in heifers during the luteal phase of the oestrous cycle after the administration of lipid X and Gram-negative endotoxin. Nine heifers whose oestrous cycles were synchronised with prostaglandin F2 alpha were assigned at random on day 10 after the second prostaglandin injection to one of the following groups. Group 1 heifers (n = 3) received 5 micrograms kg-1 bodyweight of Escherichia coli endotoxin as an intrauterine infusion and one hour later received an intravenous injection of lipid X (5 micrograms kg-1 bodyweight). The treatment was reversed in group 2 heifers (n = 3), endotoxin was administered one hour after the lipid X treatment. Group 3 heifers (n = 3) received endotoxin infusion and lipid X treatment at the same time. Similar dosages and routes of administration were used in all the groups for lipid X and endotoxin treatments. Blood samples were collected once every 15 minutes for seven hours, beginning once hour before and six hours after the initial treatment. In group 1 heifers there was a fourfold increase in serum cortisol concentrations within 30 minutes after both the treatments (from 6.5 to 24.6 ng ml-1 and from 7.3 to 29.5 ng ml-1 respectively). In group 2 heifers the cortisol concentrations increased from the baseline concentrations of 7.2 to 33.2 ng ml-1 within 30 minutes after lipid X treatment and remained at 22.5 ng ml-1 during endotoxin treatment. There was a further increase in cortisol concentrations (28.9 ng ml-1) after the endotoxin treatment.(ABSTRACT TRUNCATED AT 250 WORDS)     

Influence of exogenous growth hormone and gestational diet on sow blood and milk characteristics and on baby pig blood, body composition and performance

Sows (14) and gilts (6) were used in a 2 X 2 factorial experiment to evaluate the effect of diet and highly purified porcine growth hormone (pGH) on sow metabolic status and baby pig survival parameters. Injections were 10 mg/d pGH (GH) or sham control (SH). Diets consisted of a glucose-fat energy source (GF) or control (C). Treatments were administered the last 21 d before parturition (P). Serum GH concentrations were significantly elevated on d -19 P and d -4 P in sows receiving GH injections. Significantly elevated serum glucose and insulin concentrations were concomitantly observed in GH-treated sows, suggesting that the animals had developed a state of insulin resistance. Serum free fatty acids (FFA) were greater (P less than .01) on d -19 P for sows fed the GF diet. Fasted pigs from GH-C dams had greater (P less than .06) mean serum glucose concentrations than pigs from SH-C, SH-GF or GH-GF dams. Pigs from GH-injected sows had more (P less than .01) total body lipids at birth and tended to have increased mean FFA concentrations when compared to SH pigs. However, birth weight, number born live, number born dead, number that died and survival to 21 d were not affected by dam's injection or dietary treatment. Growth hormone injections resulted in a diabetogenic state in gestating sows and led to improved traits related to baby pig blood glucose homeostasis, including increased blood glucose, increased body lipids and a tendency toward increased liver glycogen concentrations. Injection X diet interactions indicate that dietary energy source should be regarded in future growth hormone experiments.     

Halothane-catecholamine arrhythmias in swine (Sus scrofa)

The arrhythmogenic dose of epinephrine (ADE) was determined in 6 pigs during steady-state anesthesia (1.5% halothane in O2) and steady-state anesthesia plus xylazine (1.1 mg X kg-1 X hr-1; IV infusion) and after either prazosin (alpha 1) or metoprolol (beta 1) adrenergic blockade during halothane-xylazine (H-X) anesthesia. A constant infusion (1, 2, 3, 5, and 10 micrograms X kg-1 X min-1) of freshly mixed epinephrine (100 micrograms X ml-1 in saline solution) was used to determine ADE. The ADE was defined as the total dose of epinephrine which produced 4 or more continuous or intermittent, premature, ventricular contractions within a 15-s period. The mean epinephrine total dose values during 1.5% halothane anesthesia, H-X anesthesia alone, or H-X anesthesia after either prazosin (0.1 mg X kg-1) or metoprolol (0.5 mg X kg-1) adrenergic blockade were 3.60 +/- 0.844, 2.68 +/- 0.402, 11.85 +/- 3.804, and 5.17 +/- 0.587 micrograms X kg-1, respectively. Xylazine administration did not significantly decrease ADE, although mean arterial pressure significantly increased. Prazosin administration significantly increased ADE and was associated with an increased heart rate and a decreased mean arterial pressure. We conclude that alpha 1-blockade with prazosin is more protective to epinephrine-induced arrhythmias in H-X-anesthetized pigs than is beta 1-blockade with metoprolol.     

Growth performance and carcass characteristics of pigs administered recombinant porcine somatotropin during 30 to 110 kilogram live weight

To determine growth performance during and after injection of recombinant porcine somatotropin (rpSt), crossbred Yorkshire gilts and barrows (n = 54/gender, 27 to 42 kg BW) were blocked by BW and gender (n = 3 blocks/gender). Within each block, three pigs/gender were assigned randomly to each of six pens/block. A diet containing 24.8% CP was fed ad libitum. During the live weight period of 30 to 110 kg, pigs either remained as controls (one pen/block) or were injected (i.m.) daily with rpSt (120 micrograms/kg BW) during either 30 to 60, 30 to 100, 30 to 110, 60 to 100 or 60 to 110 kg BW. Thus, three gilts and three barrows in each of three pens received each treatment. Pigs were slaughtered at either 60 kg BW (1 d after rpSt injection) or 110 kg BW (1 d, 10 d or 70 d after rpSt injection). Relative to controls, pigs injected with rpSt exhibited faster and more efficient growth during the injection period (P less than .05) but slower and less efficient growth during 10 d after cessation of injection (P less than .05). Carcasses of pigs slaughtered 1 d or 10 d after rpSt injection were leaner than controls (P less than .05), but among the pigs treated with rpSt, carcasses of pigs withdrawn from rpSt for 10 d contained more fat (P less than .05) and had a lower percentage of muscle (P less than .05) than carcasses of pigs withdrawn from rpSt for 1 d. Growth and carcass measurements were similar (P greater than .05) between controls and pigs killed 70 d after rpSt injection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Exogenous pituitary and recombinant growth hormones induce insulin and insulin-like growth factor 1 resistance in pig adipose tissue

In the present study, pigs were treated daily for 7 days with exogenous porcine growth hormone (pGH; 70 micrograms/kg BW) in order to determine whether pGH induced insulin and insulin-like growth factor 1 (1GF-1) resistance in pig adipose tissue. In the first experiment, pituitary-derived pGH (ppGH) decreased basal and insulin-stimulated lipogenesis by 50%. Insulin sensitivity decreased more than 90% as the result of pGH treatment. Sensitivity and responsiveness to IGF-1 were decreased 50% by ppGH. In a second experiment, pigs were treated daily (70 micrograms/kg BW) with exogenous pituitary pGH (ppGH) or recombinant pGH (rpGH) for 7 days in order to determine if the effects of pGH were intrinsic properties of the hormone. Both rpGH and ppGH caused similar decreases in basal rates of lipogenesis, insulin- and IGF-1-stimulated lipogenesis, and insulin and IGF-1 responsiveness in pig adipose tissue. In summary, the decrease in adipose tissue growth of pigs treated chronically with pGH is due in large part to the suppression of fatty acid synthesis and a decrease in the ability of insulin to stimulate lipid synthesis in pig adipocytes. These responses are intrinsic properties of pGH since the effects of rpGH mimicked those of ppGH. The role and importance of a decrease in IGF-1 responsiveness remains to be resolved.     

Effects of low dosages of intravenous dexamethasone on serum cortisol concentrations in the normal cat

The suppressive effects of three different low dosages of dexamethasone (5, 10 and 15 micrograms kg-1) on serum cortisol concentrations were evaluated in 10 normal cats. On four different days, serum was collected before and at two, four, six and eight hours after the intravenous administration of saline or dexamethasone. Following the administration of saline, no significant difference in mean serum cortisol concentrations was noted between the basal or postinjection values. In contrast, mean serum cortisol concentrations decreased significantly (P less than 0.05) by two hours and remained significantly below mean basal values eight hours after injection of all three dosages of dexamethasone. The degree of cortisol suppression became progressively greater as the dosages of dexamethasone were increased. After administration of the highest dose of dexamethasone (15 micrograms kg-1), serum cortisol decreased to below 5 ng ml-1 by two to four hours and remained suppressed (under 5 ng ml-1) eight hours after injection in all cats. In contrast, two of the 10 cats showed a slight escape from cortisol suppression by eight hours after injection of dexamethasone at the dosage of 10 micrograms kg-1, whereas a dosage of 5 micrograms kg-1 failed to suppress cortisol concentrations below 10 ng ml-1 at any of the sampling times in one cat and was associated with increasing serum cortisol concentrations at eight hours after injection in three cats.(ABSTRACT TRUNCATED AT 250 WORDS)     

Effects of growth hormone administration on vitamin D metabolism and vitamin D receptors in the pig

Twelve 36-kg pigs were given either 100 micrograms/kg porcine pituitary growth hormone (pGH) or placebo injections daily for 33 days. Serum was obtained weekly for analysis of minerals and vitamin D metabolites. On day 34, the pigs were sacrificed and renal and duodenal tissue were obtained for analysis of vitamin D receptor content (VDR). Animals treated with pGH grew faster and had a higher rate of bone accretion than did control animals. Serum concentrations of 1,25-dihydroxyvitamin D (1,25-(OH)2D) were significantly higher in pGH-treated pigs than in control pigs at all time points following initiation of treatment, with the greatest difference observed at day 28 (42.4 +/- 4.9 pg/ml in controls vs. 65.4 +/- 4.7 pg/ml in pGH-treated pigs). Serum 24,25-dihydroxy-vitamin D tended to be lower in pGH-treated pigs than in control pigs, being significantly lower on day 21 of the experiment (3.22 +/- .52 vs. 6.73 +/- 1.22 ng/ml, respectively). Serum concentrations of 25-hydroxyvitamin D and calcium were unaffected by pGH treatment. Kidneys of control pigs contained significantly more unoccupied vitamin D receptors than did kidneys from pGH-treated pigs (73.3 +/- 4.3 vs. 58.3 +/- 4.1 fmoles/mg protein). Duodenal tissue unoccupied vitamin D receptor content was similar in both pGH-treated (245 +/- 17.9 fmoles/mg protein) and control (263 +/- 21.8 fmoles/mg protein) pigs. Duodenal occupied vitamin D receptor concentration was similar in both pGH-treated (6.8 +/- .75 fmoles/mg protein) and control pigs (5.32 +/- .77 fmoles/mg protein).(ABSTRACT TRUNCATED AT 250 WORDS)